Douglas A. Hamilton
Directeur Général chez METASTAT, INC.
Profil
Mr. Douglas A.
Hamilton is a Principal at New Biology Ventures LLC.
Previously, he was the Chief Financial Officer at Javelin Pharmaceuticals Inc., (Formerly Intrac Inc.) from March 1999 to May 1, 2006 and served as Chief Operating Officer from December 2004 to February 2006 and also served as Chief Accounting Officer and Treasurer.
He is a Founder at Intrac Inc. and served as its Secretary.
He was the Chief Operating Officer at IDDS (Innovative Drug Delivery Systems ...
Inc.) since April 2001 and Chief Financial Officer since March 1999.
Previously, he served as Chief Financial Officer and Project Manager of Trisenox(R) at PolaRx BioPharmaceuticals.
From March 1999 to August 2002, he also concurrently served as Director, Business Development at Paramount Capital Investments, LLC.
From October 1997 to March 1999, he served as Project Manager at Zithromax(R) and Vfend(R) in addition to being a member of the Strategic Asset Management (SAM) task force in Central Research at Pfizer, Inc. From August 1993 to October 1997.
Mr. Hamilton was a Project Manager at Amgen Inc. for EPOGEN(R), Aransep(R) and STEMGEN(R), among other products, and assumed responsibility for developing and leading a research and development portfolio management system.
He has also served in various capacities at other biopharmaceutical companies including sales and marketing at Pharmacia, business development at NPS Allelix Biopharmaceuticals, Inc. and research at Pasteur Merieux Connaught.
Mr. Hamilton holds a M.B.A.
from the Richard Ivey School of Business and a B.S.
in Molecular Biology and Molecular Genetics from the Department of Medical Genetics at the University of Toronto.
Postes actifs de Douglas A. Hamilton
| Sociétés | Poste | Début |
|---|---|---|
| METASTAT, INC. | Directeur Général | 17/06/2015 |
Vasomune Therapeutics, Inc.
 Vasomune Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Vasomune Therapeutics, Inc. operates as an early stage biopharmaceutical company. It develops medicines to harness the body’s ability to defend against illness by modifying cellular response to disease. The company is headquartered in Toronto, Canada. | Directeur Général | 09/10/2018 |
Anciens postes connus de Douglas A. Hamilton
| Sociétés | Poste | Fin |
|---|---|---|
S.E.A. Medical Systems, Inc.
 S.E.A. Medical Systems, Inc. Medical SpecialtiesHealth Technology S.E.A. Medical Systems, Inc. develops medical devices that catch serious or life-threatening intravenous drug errors. It specializes in developing medical devices that catch serious or life-threatening intravenous drug errors before they harm patients. It has created a disruptive platform technology with life-saving product applications, allowing for the identification and characterization of medical solutions in real time. The firm offers IV Check that validates IV preparations and measures pharmacy returns to detect narcotic or scheduled drug diversion. The company was founded in October 2008 by James W. Bennett, Leo Matsiev and Michael J. Weickert and is headquartered in Emerald Hills, CA. | Directeur Financier/CFO | 01/01/2014 |
Javelin Pharmaceuticals, Inc.
 Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | Directeur Financier/CFO | 12/05/2006 |
Intrac, Inc.
 Intrac, Inc. Financial ConglomeratesFinance The Group's principal activity is to develop new drug and improve formulations of existing drug that target current unmet and underserved medical need primarily in the pain management market. It develops simple and user-friendly products, including new modes and routes of delivery for drugs optimized for relieving moderate-to-severe pain. The Group is in the development stage. | Directeur Financier/CFO | 09/09/2005 |
PolaRx Biopharmaceuticals
 PolaRx Biopharmaceuticals Miscellaneous Commercial ServicesCommercial Services Part of Swedish Orphan Biovitrum AB, PolaRx Biopharmaceuticals is a company that manufactures TriOxide drugs for the treatment of leukemia and other cancers. The company is based in New York, NY. The company was founded by Fred H. Mermelstein, Peter Morgan Kash, Raymond P. Warrell. PolaRx Biopharmaceuticals was acquired by CTI BioPharma Corp., part of Swedish Orphan Biovitrum AB from June 27, 2023 on January 13, 2000 for $17.50 million. | Directeur Financier/CFO | 31/07/2002 |
| Paramount Capital Investments LLC | Corporate Officer/Principal | 28/02/1999 |
Formation de Douglas A. Hamilton
| University of Toronto | Undergraduate Degree |
| Western University | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| METASTAT, INC. | Producer Manufacturing |
| Entreprise privées | 11 |
|---|---|
Intrac, Inc.
Intrac, Inc. Financial ConglomeratesFinance The Group's principal activity is to develop new drug and improve formulations of existing drug that target current unmet and underserved medical need primarily in the pain management market. It develops simple and user-friendly products, including new modes and routes of delivery for drugs optimized for relieving moderate-to-severe pain. The Group is in the development stage. | Finance |
Innovative Drug Delivery Systems, Inc.
 Innovative Drug Delivery Systems, Inc. Pharmaceuticals: MajorHealth Technology IDDS is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical need in the pain management market. IDDS’s product candidates address the market segment for prescription medications focused on treating acute and episodic moderate-to-severe pain associated with breakthrough cancer pain, post operative pain, orthopedic injury, procedural pain, burn pain and trauma. The product candidates offer enhanced pain relief, fewer adverse side effects and faster relief of pain compared to other currently available treatments. | Health Technology |
S.E.A. Medical Systems, Inc.
S.E.A. Medical Systems, Inc. Medical SpecialtiesHealth Technology S.E.A. Medical Systems, Inc. develops medical devices that catch serious or life-threatening intravenous drug errors. It specializes in developing medical devices that catch serious or life-threatening intravenous drug errors before they harm patients. It has created a disruptive platform technology with life-saving product applications, allowing for the identification and characterization of medical solutions in real time. The firm offers IV Check that validates IV preparations and measures pharmacy returns to detect narcotic or scheduled drug diversion. The company was founded in October 2008 by James W. Bennett, Leo Matsiev and Michael J. Weickert and is headquartered in Emerald Hills, CA. | Health Technology |
| Allelix Biopharmaceuticals, Inc. | Health Technology |
PolaRx Biopharmaceuticals
PolaRx Biopharmaceuticals Miscellaneous Commercial ServicesCommercial Services Part of Swedish Orphan Biovitrum AB, PolaRx Biopharmaceuticals is a company that manufactures TriOxide drugs for the treatment of leukemia and other cancers. The company is based in New York, NY. The company was founded by Fred H. Mermelstein, Peter Morgan Kash, Raymond P. Warrell. PolaRx Biopharmaceuticals was acquired by CTI BioPharma Corp., part of Swedish Orphan Biovitrum AB from June 27, 2023 on January 13, 2000 for $17.50 million. | Commercial Services |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | Health Technology |
| Pharmacia, Inc. | |
| Pasteur Mérieux Connaught | |
| Paramount Capital Investments LLC | |
New Biology Ventures LLC
 New Biology Ventures LLC Investment ManagersFinance New Biology Ventures LLC (New Biology Ventures) is a venture capital firm founded in 2007 by Douglas A. Hamilton. The firm is headquartered located in San Francisco, California. | Finance |
Vasomune Therapeutics, Inc.
Vasomune Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Vasomune Therapeutics, Inc. operates as an early stage biopharmaceutical company. It develops medicines to harness the body’s ability to defend against illness by modifying cellular response to disease. The company is headquartered in Toronto, Canada. | Health Technology |
